Clinical trial NCT00419419: Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Official title: Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Raynaud's Disease
Scleroderma
Autoimmune Diseases
Keywords: Raynaud's
Lead sponsor: MediQuest Therapeutics
Sponsor class: INDUSTRY
First posted: 2007-01-08
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Detailed description: The purpose of this clinical study is to determine, in a controlled fashion, the ability of Topical AmphiMatrix formulation with Nitroglycerin (MQX-503) to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases such as scleroderma.

Eligibility criteria: Inclusion Criteria:

* Outpatients, 18 years to 70 years.
* Patients with a clinical diagnosis of Raynaud's phenomenon.
* Patients who are willing to discontinue current vasodilator therapies.
* Patients who agree not to use any other investigational medications or approved therapies to treat Raynaud's phenomenon and its symptoms while participating in this study.
* Negative pregnancy test in fertile women.
* Patients who are able to give written informed consent and comply with all study requirements.

Exclusion Criteria:

* Patients who concurrently use any nitrate medication or medications known to interact with Nitroglycerin.
* Patients who concurrently use any medication or device which might interfere with the study medication.
* Patients who have a known allergy to Nitroglycerin or common topical gel ingredients.
* Patients with a history of headaches.
* Patients who have a history of an unstable medical problem.
* Patients with cognitive or language difficulties.
* Patients who, within the past three months, have had either a myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension, or uncontrolled hypertension.
* Patients who participated in a study of any investigational drug within four weeks prior to Visit 1.
* Patients who have screening laboratory values which are 20% or greater of the upper or lower limit of normal.
* Patients who have had major surgery within six months of Visit 1.
* Patients with interfering skin conditions.
* Pregnant or nursing women.

Primary outcomes:
measure: Reduction in Raynaud's Condition Score
Secondary outcomes:
measure: Frequency and Severity of adverse events
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Standford Medical School
state: California
city: Farmington
country: United States
facility: University of Connecticut
state: Connecticut
city: Washington
country: United States
facility: Georgetown University Medical Center
state: District of Columbia
city: Baltimore
country: United States
facility: Johns Hopkins Bayview Medical Center
state: Maryland
city: Albany
country: United States
facility: The Center for Rheumatology
state: New York
city: Durham
country: United States
facility: Duke University
state: North Carolina
city: Lund
country: Sweden
facility: Lund University Hospital
city: Bath
country: United Kingdom
facility: Royal National Hospital for Rheumatic Diseases
city: Dundee
country: United Kingdom
facility: Ninewells Hospital and Medical School
city: Leeds
country: United Kingdom
facility: University of Leeds
city: London
country: United Kingdom
facility: Royal Free Hospital
city: Salford
country: United Kingdom
facility: Hope Hospital
Study officials:
References: